SAR3419

DRUG5 trials

Sponsors

Sanofi

Conditions

Acute Lymphocytic LeukaemiaDiffuse Large B-Cell LymphomaDiffuse Large B-cell LymphomaLymphomaNon-Hodgkin

Phase 1

Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

CompletedNCT00549185

SanofiLymphoma, Non-Hodgkin

Start: 2007-10-31End: 2012-01-31Updated: 2012-02-14

SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

CompletedNCT00796731

SanofiLymphoma, Non-Hodgkin

Start: 2008-10-31End: 2012-06-30Updated: 2012-07-17

Phase 2

SAR3419 in Acute Lymphoblastic Leukemia

TerminatedNCT01440179

SanofiAcute Lymphocytic Leukaemia

Start: 2011-10-31End: 2014-05-31Updated: 2022-09-21

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

CompletedNCT01470456

SanofiDiffuse Large B-Cell Lymphoma

Start: 2011-11-30End: 2014-09-30Updated: 2014-11-13

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

CompletedNCT01472887

SanofiDiffuse Large B-cell Lymphoma

Start: 2012-01-31End: 2016-09-30Updated: 2018-01-25

Related Papers

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

Blood2015-12-03

Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).

Journal of Clinical Oncology2014-05-2016 citations